Evommune (NYSE:EVMN) Director David Cohen Sells 6,056 Shares

Evommune, Inc. (NYSE:EVMN) Director David Cohen sold 6,056 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $20.33, for a total transaction of $123,118.48. Following the completion of the transaction, the director owned 17,609 shares of the company’s stock, valued at approximately $357,990.97. The trade was a 25.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Evommune Stock Performance

Shares of EVMN opened at $19.78 on Thursday. The stock has a market cap of $712.62 million and a price-to-earnings ratio of -2.08. The company’s fifty day moving average is $23.98. Evommune, Inc. has a 1-year low of $13.89 and a 1-year high of $33.20.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. Research analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on EVMN shares. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Evommune in a research note on Tuesday, May 26th. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Evercore reissued an “outperform” rating and set a $55.00 price objective on shares of Evommune in a research report on Tuesday, February 10th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $49.25.

Institutional Investors Weigh In On Evommune

A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new position in Evommune in the 4th quarter worth $34,000. Strs Ohio bought a new position in Evommune in the 1st quarter worth $41,000. The Manufacturers Life Insurance Company bought a new position in Evommune in the 4th quarter worth $179,000. XTX Topco Ltd bought a new position in Evommune in the 4th quarter worth $321,000. Finally, Oxford Asset Management LLP bought a new position in Evommune in the 4th quarter worth $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.